On the evening of October 26, Haier Biotech (688139.SH) disclosed the third quarterly report for 2021. The report shows that the company’s Internet of Things strategy in the first three quarters was fully deepened, and revenue continued to grow at a high rate. Operating income was 1.52 billion yuan, a year-on-year increase of 54.89%; net profit was 700 million yuan, a year-on-year increase of 155.2%; net profit attributable to parent company was 698 million yuan. , An increase of 156.28% year-on-year.
During the reporting period, Haier Biosciences fully grasped the opportunities of users and the industry, continued to consolidate its core advantages through the convergence of technological innovation and market channels, and deepened the advancement of the Internet of Things biosafety technology ecological construction, and continued to accumulate sustainable growth potential to ensure The overall performance rose steadily.
The Internet of Things business continues to penetrate the domestic and overseas markets to continue high growth
As a leading company in the field of IoT biosafety, Haier Biosciences continues to expand the scene ecology and promote its own IoT strategic process. In the first three quarters, the business of each scene has maintained a comprehensive and stable improvement, achieving sample safety, drug and reagent safety, vaccine safety, and blood safety. The main business scenario revenue increased by 27.54%, 57.78%, 70.01% and 419.73% respectively. Haier Biotech uses differentiated solutions to meet the customized needs of users. In the first three quarters, the revenue of the Internet of Things solution business has increased by 155.45%, and the proportion of overall revenue has increased to 28.71%. In the first three quarters, the company’s first smart mobile vaccination program has covered more than 200 prefectures and cities across the country for new crown vaccination, and achieved revenue of more than 60 million yuan. The Smart City Blood Network was launched in Yichang, and the nationalization process continued to advance. The company has delivered Xianning, Urumqi blood center automated blood stations and other projects, won the bid for the Kunming Blood Center Chenggong cold storage project, and the application market continues to expand.
Driven by the Internet of Things business, as Haier Biology continues to deepen its global layout, both domestic and overseas markets have maintained steady growth. Data show that domestic and overseas revenues were 1.123 billion yuan and 391 million yuan in the first three quarters, an increase of 66.56% and 32.79% year-on-year. Diversified product solutions such as carbon dioxide incubators and biological safety cabinets have successively entered overseas markets and have been recognized by many European and American users. With the continuous enrichment of the product and program lineup and the further opening of overseas markets, revenue in the third quarter increased significantly, with a year-on-year increase of 79.15%. The company’s recent approval of the “Qualification of General Contracting Enterprise for Foreign Aid Material Projects by the Ministry of Commerce” will be conducive to the diversification of overseas operations and the continuous improvement of brand influence in the future.
Technological innovation and market convergence have strong sustainable growth potential
Haier Biosciences insists on scientific and technological innovation to lead industrial reforms, actively deploys new growth points for biosafety solutions, and continues to nurture new growth drivers. During the reporting period, the company continued to emerge new products and new solutions for sample safety segmentation scenarios such as sample pre-processing, biological culture, and cell preparation, and more than 20 new patents were added to related products. Independently developed and launched the program cooling instrument, the new series of carbon dioxide incubators and centrifuges and other products, and successfully applied to Ruijin Hospital, University of Science and Technology of China, Shanxi Medical University and other production, education and research units. Among them, the centrifuge was accepted by the Ministry of Science and Technology “Hundred Cities and Hundred Parks” project; the multiple technical advantages and cell culture effects of the Yunyu CO₂ incubator were recognized by the German EBM, and the “Cell Preparation Smart IoT Full Scene Solution” project won the World Internet of Things Expo “Three New” achievements. In the third batch of national service-oriented manufacturing demonstration lists announced by the Ministry of Industry and Information Technology recently, Haier Biomedical was successfully selected.
On the channel side, Haier Biosciences accelerated the construction of a global network system, explored new business growth opportunities, and opened up new incremental markets. The company’s vertical sinking and horizontal expansion have been carried out simultaneously, and a market network system of “region→channel→scenario” has been established in the country: it has deepened public health capacity building for city and county-level primary care, and delivered multiple regional health construction projects; and at the same time, it has made efforts The network construction of the new biosafety industry opens up new regional network systems in Shanghai, Hangzhou, and Beijing. Overseas, we continued to expand the breadth and depth of the international market network, adding 184 dealers, and establishing localized sales teams in the United States, Vietnam and other countries to more closely follow the needs and services of local users and enhance user stickiness; helping the company The user’s single scene extends to multiple scenes, accelerating the expansion of development advantages.
Industry insiders pointed out that the current biosafety track is in a golden development period, favorable policies are intensively released, and market demand is diversified. As a leading company in the biosafety technology ecosystem of the Internet of Things, Haier Biosciences actively leverages its first-mover advantages, both internally and externally, to improve its sustainable operation capabilities. It is expected to fully benefit from the favorable environment of the industry and continue its healthy and sustainable development trend.Return to Sohu to see more
Editor:
Disclaimer: The opinions of this article only represent the author himself. Sohu is an information publishing platform. Sohu only provides information storage space services.
.